
Find Reports
Select Report Type
Reimbursement Review
Displaying 201 - 225 of 1264
Please scroll or swipe to the right to view the full content.
Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
---|---|---|---|---|---|---|---|---|
Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | PC0275-000 | |||
Xpovio | selinexor | Multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | PC0276-000 | |||
Brukinsa | zanubrutinib | Mantle cell lymphoma (MCL) | Do not reimburse | Complete | PC0267-000 | |||
Albrioza | sodium phenylbutyrate and ursodoxicoltaurine | Amyotrophic lateral sclerosis (ALS) | Reimburse with clinical criteria and/or conditions | Complete | SR0711-000 | |||
Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | SR0706-000 | |||
Nexviazyme | avalglucosidase alfa | Pompe disease | Reimburse with clinical criteria and/or conditions | Complete | SR0703-000 | |||
Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0274-000 | |||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PG0258-000 | |||
Lenvima and Keytruda | lenvatinib and pembrolizumab | advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0268-000 | |||
Oxervate | cenegermin | Neurotrophic keratitis | Reimburse with clinical criteria and/or conditions | Complete | SR0704-000 | |||
Vyndaqel | tafamidis | Transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | SF0722-000 | |||
Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation, 6 years and older | Reimburse with clinical criteria and/or conditions | Complete | SR0710-000 | |||
Firdapse | amifampridine phosphate | Lambert-Eaton Myasthenic Syndrome, adults | Reimburse with clinical criteria and/or conditions | Complete | SR0664-000 | |||
HyQvia | immune globulin human and recombinant human hyaluronidase | Humoral immunodeficiency | Reimburse with clinical criteria and/or conditions | Complete | ST0695-000 | |||
Rinvoq | upadacitinib | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | SR0685-000 | |||
Libtayo | cemiplimab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0262-000 | |||
Osphena | ospemifene | Dyspareunia, vaginal dryness | Reimburse with clinical criteria and/or conditions | Complete | SR0709-000 | |||
Qinlock | ripretinib | Gastrointestinal stromal tumours | Reimburse with clinical criteria and/or conditions | Complete | PC0265-000 | |||
Retevmo | selpercatinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0261-000 | |||
Intrarosa | prasterone | Postmenopausal vulvovaginal atrophy | Reimburse with clinical criteria and/or conditions | Complete | SR0707-000 | |||
Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ST0702-000 | |||
Tavalisse | fostamatinib | Chronic immune thrombocytopenia | Do not reimburse | Complete | SR0701-000 | |||
Bimzelx | bimekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | SR0698-000 | |||
Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | PC0252-000 | |||
Lorbrena | lorlatinib | ALK-positive locally advanced or metastatic non-small cell lung | Reimburse with clinical criteria and/or conditions | Complete | PC0249-000 |
Health Technology Review
Displaying 201 - 225 of 590
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 39 of 39
View All Reports
Displaying 201 - 225 of 2100
Please scroll or swipe to the right to view the full content.
Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
---|---|---|---|---|---|---|---|
Optimal Wait Times | Health Technology Review | In Progress | CM0014-000 | ||||
pembrolizumab | Reimbursement Review | Complete | PC0344-000 | ||||
durvalumab | Reimbursement Review | Suspended | PC0372-000 | ||||
Long-Acting Inhaled Drugs for Chronic Obstructive Pulmonary Disease | Health Technology Review | Therapeutic Review | Active | TR0016-000 | |||
Adult Classical Hodgkin Lymphoma | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0052-000 | |||
Care for Adults Following Laryngectomy | Health Technology Review | Rapid Review | Active | RC1551-000 | |||
pembrolizumab | Reimbursement Review | Complete | PC0343-000 | ||||
elranatamab | Reimbursement Review | Complete | PC0315-000 | ||||
aflibercept 8mg/0.07mL | Reimbursement Review | Complete | SR0812-000 | ||||
Midazolam Compared With Lorazepam in Adults to Control Seizures | Health Technology Review | Rapid Review | Completed | RC1554-000 | |||
Federal, Provincial, and Territorial Coverage of Diagnostic Sleep Studies | Horizon Scan | Environmental Scan | Active | ES0382-000 | |||
Utilization of Long-Acting Injectable Antipsychotics | Health Technology Review | Technology Review | In Progress | HC0098-000 | |||
Pharmaceutical Reviews Update — Issue 52 | Reimbursement Review | Pharmaceutical Review Update | |||||
epcoritamab | Reimbursement Review | Complete | PC0334-000 | ||||
everolimus | Reimbursement Review | Complete | SX0814-000 | ||||
rivaroxaban | Reimbursement Review | Complete | SX0750-000 - SR0750-000 | ||||
eltrombopag | Reimbursement Review | Complete | SX0777-000 | ||||
nab-paclitaxel | Reimbursement Review | Complete | PX0360-000 | ||||
Nab-paclitaxel | Reimbursement Review | Complete | PX0354-000 | ||||
Pembrolizumab | Reimbursement Review | Complete | PX0346-000 | ||||
Nivolumab and Ipilimumab | Reimbursement Review | Complete | PX0347-000 | ||||
Nab-paclitaxel | Reimbursement Review | Complete | PX0348-000 | ||||
panitumumab | Reimbursement Review | Complete | PX0333-000 | ||||
bevacizumab and lomustine | Reimbursement Review | Complete | PX0318-000 | ||||
Review of Guidelines on Bupropion for Depression | Health Technology Review | Rapid Review | Completed | RC1558-000 |